Using benralizumab — a medication approved in the U.S. for a rare type of asthma — off-label as an add-on to standard induction treatment resulted in a high rate of disease remission in people with eosinophilic granulomatosis with polyangiitis (EGPA) and severe asthma. That’s according to a real-world study in…
News
The production of new B-cells, a type of immune cell that helps fight infections but is also involved in the abnormal immune attacks that drive ANCA-associated vasculitis (AAV), is dysfunctional in people with the autoimmune disease, a study found. The findings could help shed light on the biological underpinnings…
ANCA-associated vasculitis (AAV) patients with neurological manifestations are more than three times more likely to have large blood vessel involvement (LVI), according to a multicenter study in France and Belgium. Data also showed that LVI most commonly affected the aorta — the large artery that delivers oxygen-rich blood to…
While it’s rare in children, ANCA-associated vasculitis (AAV)-related glomerulonephritis, that is, an inflammation of the glomeruli, the kidneys’ filtering units, is associated with high rates of kidney failure or death, a study shows. Also, scar tissue accumulating in the glomeruli, other kidney tissue abnormalities, and high protein levels in…
Treatment with the asthma medication montelukast may trigger eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV), a case-based review study suggests. The study, “Eosinophilic granulomatosis with polyangiitis and its association with montelukast: a case-based review,” was published in Clinical Rheumatology. AAV is a…
The U.S. Food and Drug Administration (FDA) has given Nkarta the green light to launch a clinical trial testing its cell therapy candidate NKX019 in people with ANCA-associated vasculitis (AAV) and other autoimmune disorders. The upcoming multicenter trial, dubbed Ntrust-2, is expected to initially recruit as many as…
Tavneos (avacopan) is better than the glucocorticoid prednisone at promoting disease remission, lowering relapse rates, and improving quality of life in ANCA-associated vasculitis (AAV) patients with active ear, nose, or throat (ENT) manifestations. That’s according to new subgroup analyses from the Phase 3 ADVOCATE clinical trial (NCT02994927).
Melodia Therapeutics has acquired the exclusive rights to develop, manufacture, and commercialize MDI-0151, a candidate therapy for hard-to-treat ANCA-associated vasculitis (AAV) and other disorders marked by overactivation of neutrophils, a type of immune cell. Melodia said it will “rapidly initiate” investigational new drug (IND)-enabling studies in preparation of a…
The U.S. Food and Drug Administration (FDA) has given NovelMed the green light to initiate a Phase 2 clinical trial to test its investigational antibody-based therapy ruxoprubart in adults with ANCA-associated vasculitis (AAV). The Phase 2 study (NCT06226662) will evaluate the therapy’s safety and efficacy in up…
Inflammatory bowel disease (IBD) — a chronic disease where the bowel becomes inflamed, causing recurring lower abdominal pain and diarrhea — can overlap with ANCA-associated vasculitis (AAV) and is often diagnosed first, a study found. The finding suggests a possible link between the two diseases, and that having IBD…
Recent Posts
- Preparing for surgery with ANCA vasculitis is a team effort
- Serious heart disease seen early in newly diagnosed EGPA patients
- Gamma delta CAR T-cells are being tested to ‘reset’ AAV immune system
- Finding a little light on dark winter days is key with ANCA vasculitis
- Real-world data show high AAV remission rates with Tavneos